AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ABEC Sets Benchmark in Productivity for Flexible Biopharmaceutical Manufacturing

September 10, 2019
ABEC Sets Benchmark in Productivity for Flexible Biopharmaceutical Manufacturing
ABEC Sets Benchmark in Productivity for Flexible Biopharmaceutical Manufacturing

BETHLEHEM, Pa.--(BUSINESS WIRE)--Sep 10, 2019--

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, today introduced the Flexible Manufacturing Platform, a fully-customizable cell culture platform for flexible, high-volume biopharmaceutical production. The Flexible Manufacturing Platform is based on ABEC’s scalable CSR® single-use and core stainless steel systems capabilities, and enables flexible facilities to produce twice the product output from bioreactor to bulk fill. In addition, ABEC’s unique non-proprietary supply chain approach for single-use materials, instruments and components provides maximum adaptability over the facility lifetime.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005803/en/

(Graphic: Business Wire)

Key elements of the Flexible Manufacturing Platform include ABEC’s CSR single-use bioreactors with production volumes up to 4,000L, CSR General Mix systems with production volumes up to 5,000L, and Solutions Hold systems with production volumes up to 4,000L. The CSR products lead the industry in volume and performance, and the Flexible Manufacturing Platform leverages these elements in facility designs that double cell culture and downstream capacity while utilizing floor space comparable to current 2,000L-based facilities. The Flexible Manufacturing Platform designs also improve operational efficiency by elevating buffer above the points of use rather than current methods involving pushing totes or in-line conditioning.

“ABEC’s Flexible Manufacturing Platform is consistent with our mission to provide the industry’s most productive and cost-effective solutions for biopharmaceutical manufacturing,” said Scott Pickering, ABEC President and CEO. “ ABEC is now providing total solutions utilizing both single-use and stainless steel technologies, and can objectively support customers in developing designs optimized for their particular business needs.”

About ABEC

Since 1974, ABEC has been a leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. A majority of the world’s pharmaceutical and biotech companies are ABEC customers with many of today’s leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC’s unique value is based on long experience, complete in-house capabilities, a customized, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities ABEC’s turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. www.abec.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190910005803/en/

CONTACT: ABEC

Susan Cooper Curcio

+1 (610) 861 4666

scurcio@abec.com

KEYWORD: CHINA NORTH AMERICA ASIA PACIFIC EUROPE UNITED STATES UNITED KINGDOM PENNSYLVANIA

INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL SUPPLIES MANUFACTURING HEALTH PHARMACEUTICAL MEDICAL DEVICES OTHER MANUFACTURING CLINICAL TRIALS

SOURCE: ABEC

Copyright Business Wire 2019.

PUB: 09/10/2019 11:11 AM/DISC: 09/10/2019 11:11 AM

http://www.businesswire.com/news/home/20190910005803/en

All contents © copyright 2019 The Associated Press. All rights reserved.